Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel-bevacizumab +/- Atezolizumab in Advanced Non-squamous NSCLC
NCT05781308Phase 2Active, not recruiting
- Sponsor
- IFCT
- Start
- Apr 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by IFCT. Primary endpoint: Progression Free Survival at 6 months. Started Apr 2023; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05781308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05781308.